Add this topic to your myFT Digest for news straight to your inbox
Firms can play an increasingly central role in unlocking investment for projects to materialise
Market leader rejects accusations of exposing amateur investors to risks they may not appreciate
Big pharma groups pay higher charges for access to most promising molecules
The departure letter of Groupon’s Andrew Mason raises questions about the right way to leave
International Edition